Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

346

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2027

Conditions

Limited Stage Small Cell Lung Cancer

Interventions

DRUG

Sugemalimab

Recombinant anti-PD-L1 fully human monoclonal antibody

DRUG

Placebo

Placebo of Sugemalimab

Trial Locations (1)

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER